APP
HAE icon

Alpha Paradigm Partners’s Haemonetics HAE Stock Holding History

Alpha Paradigm Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,051
Closed -$736K – 591
2021
Q2 		$736K Buy
+11,051
New +$782K 0.28% 116

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Alpha Paradigm Partners's HAE Position: Q3 2021 in Review

Alpha Paradigm Partners sold out of Haemonetics (HAE) in Q3 2021, closing a stake of 11,051 shares — an estimated $736K sold.

Alpha Paradigm Partners first reported a position in HAE in Q2 2021 and held it in 1 quarter. The position peaked at $736K in Q2 2021. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

  • Alpha Paradigm Partners reported no remaining Haemonetics position as of Q3 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 11,051 Haemonetics shares in Q3 2021, an estimated $736K.
  • Alpha Paradigm Partners first reported a position in Haemonetics in Q2 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's Haemonetics position peaked at $736K in Q2 2021.
  • 245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on Alpha Paradigm Partners's 13F filing for Q3 2021, filed 15 Nov 2021.